Edwards Lifesciences (NYSE:EW) Given New $110.00 Price Target at BTIG Research

Edwards Lifesciences (NYSE:EW) had its price target increased by research analysts at BTIG Research from $100.00 to $110.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. BTIG Research’s target price points to a potential upside of 20.44% from the company’s previous close.

EW has been the topic of a number of other reports. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Evercore reissued an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.39.

Edwards Lifesciences Stock Up 0.6%

Shares of NYSE EW opened at $91.33 on Tuesday. The firm has a market cap of $52.59 billion, a PE ratio of 48.58, a P/E/G ratio of 2.28 and a beta of 0.87. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $92.88. The company’s fifty day simple moving average is $84.66 and its 200 day simple moving average is $83.31. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares in the company, valued at $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 81,038 shares of company stock worth $6,683,255 over the last 90 days. Company insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently bought and sold shares of the company. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the third quarter valued at about $25,000. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $26,000. RMG Wealth Management LLC purchased a new position in Edwards Lifesciences during the first quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. purchased a new position in Edwards Lifesciences during the fourth quarter worth about $27,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.